Corporate ActionMay 20, 2026, 04:25 PM
20/20 Biolabs Raises $5M Series E Preferred Stock; Converts Debt & Preferred
AI Summary
20/20 Biolabs, Inc. reported a net loss of $(2,174,836) for Q1 2026, an increase from $(764,577) in Q1 2025, with revenues decreasing to $353,375. The company significantly strengthened its capital structure by raising $5 million through the issuance of Series E convertible preferred stock and warrants. Additionally, all outstanding Series A, A-1, A-2, B, C, and D preferred stock, along with convertible debt, were converted into common stock, resulting in a shift from a stockholders' deficit to $2,552,886 in equity.
Key Highlights
- Issued $5,000,000 in Series E convertible preferred stock and warrants in Q1 2026.
- Converted all Series A, A-1, A-2, B, C, and D preferred stock to common stock.
- Converted $834,812 of convertible notes and accrued interest to common stock.
- Shifted from a stockholders' deficit of $(19,225) to equity of $2,552,886 as of March 31, 2026.
- Net loss increased to $(2,174,836) in Q1 2026 from $(764,577) in Q1 2025.
- Revenues decreased to $353,375 in Q1 2026 from $553,820 in Q1 2025.
- Cash and cash equivalents increased to $4,219,099 as of March 31, 2026, from $1,025,987.
- Net cash used in operating activities increased to $(1,288,960) in Q1 2026.
Price Impact
More from AIDX